참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | Hydrochloric Acid | HCID 313 | — |
| 반응물 | Doxepin | HCID 3158 | — |
| 반응물 | Oxymetazoline | HCID 4636 | — |
| 반응물 | 1-Propanamine, 3-(dibenz[b,e]oxepin-11(6H)-ylidene)-N,N-dimethyl-, hydrochloride (1:1) | HCID 14675 | — |
| 반응물 | Oxymetazoline Hydrochloride | HCID 66259 | — |
| 반응물 | HCID 178481191 | HCID 178481191 | — |
| 생성물 | Lidocaine Hydrochloride | HCID 6314 | — |
반응 단계
A 2% composition of doxepin in the nanolipid-vesicle composition of Preparation 2 above was prepared by mixing doxepin hydrochloride with the nanolipid vesicle formulation as described in Preparation 2 which had been modified by the addition of Keltrol to render a thick creamy consistency, in a mass/mass ratio of 2:98 with the aid of a high speed stirrer. The composition is designated DOXIPEX CREAM. (b) In similar manner a 1.7307% composition of Lidocaine Hydrochloride was prepared and designated LIDAREX LOTION. (c) A 0.3% composition of Scopolamine HBR was also prepared in the same manner and designated MZL Scopolamine. (d) A 0.5% nasal spray composition of Oxymetazoline HCl was also prepared in the same manner with some modification and designated Oxymetazoline MZL. (e) A 0.5% injection formulation of Bupivicaine HCl was further prepared in the same manner but with some modification and designated Bupivicaine MZL.
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| 특허 번호 | US08329685B1 |
|---|
| 출처 데이터셋 | uspto-grants-2012_12 |
|---|
| ORD ID | ord-518d72c2bc324f2499a26c914e44744d |
|---|
| 출처 메모 | uspto-grants-2012_12 |
|---|
